Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$891.07 USD

891.07
1,751,171

+6.59 (0.75%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo

Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.

Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why

Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.

Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates

Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.

Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat

Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.

5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down

Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.

Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report

Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.

J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod

J&J (JNJ) gets FDA advisory committee's positive recommendation for its investigational nasal spray, Spravato (esketamine) for treatment-resistant depression in adults.

The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion

The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion

Swarup Gupta headshot

5 Tiny Biotech Stocks With Superb Growth Potential

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

Mark Vickery headshot

Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp

Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Eli Lilly (LLY) and U.S. Bancorp (USB).

Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake

Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco

Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

Incyte Down as FDA Extends Review Period of Jakafi for GVHD

The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.

Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs

Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.

Stock Market News For Feb 7, 2019

U.S. stocks closed lower on Wednesday following disappointing earnings results from videogame companies.

Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth

Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.

Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.

Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued outlook for earnings and sales. Stock drops in pre-market trading.

Sanofi's Myeloma Candidate Meets Goal in Phase III Study

Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.

Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer

Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.

Roche Submits sBLA to FDA for Label Expansion of Kadcyla

Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.

Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines

Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.

Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies

Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.